Asunto(s)
Vacunas contra Haemophilus , Vacunas contra Hepatitis B , Padres , Vacuna Antipolio de Virus Inactivados , Humanos , China , Vacunas contra Haemophilus/economía , Vacunas contra Hepatitis B/economía , Vacunas contra Hepatitis B/administración & dosificación , Estudios Transversales , Padres/psicología , Vacuna Antipolio de Virus Inactivados/economía , Vacuna Antipolio de Virus Inactivados/administración & dosificación , Vacunas Combinadas/economía , Aceptación de la Atención de Salud/psicología , Encuestas y Cuestionarios , Vacunación/economía , Vacunación/psicología , Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , LactanteRESUMEN
OBJECTIVES: To evaluate cost implications of a hexavalent vaccine (diphtheria, tetanus, and acellular pertussis [DTaP]-inactivated polio vaccine [IPV]-hepatitis B [HB]-Haemophilus influenzae type B [Hib] polysaccharide conjugated to T protein [PRPâ¼T]) as an alternative to DT-whole-cell pertussis (wP)-HB//Hib, DTwP, IPV, and oral polio vaccines in the Expanded Program on Immunization schedule in Colombia. METHODS: Primary vaccination (DTaP-IPV-HB-PRPâ¼T or DTwP-HB-Hib + IPV [2, 4, 6 months]) and booster (DTaP-IPV-HB-PRPâ¼T or DTwP + oral polio vaccine [18 months]) (scenario 1) and primary vaccination only (DTaP-IPV-HB-PRPâ¼T or DTwP-HB-Hib + IPV) (scenario 2) were evaluated. An estimated cost-minimization analysis was based on a micro costing technique for vaccination-associated activities. Adverse event (AE)-associated costs, out-of-pocket costs, and productivity losses for caregivers were included. A budget impact (12-month temporal horizon) was estimated according to the distribution of full-term and premature infants. A 5% annual discount rate was used. A 2-way univariate (tornado) analysis evaluated which variables had the greatest impact on the overall cost. RESULTS: DTaP-IPV-HB-PRPâ¼T resulted in a cost increase of 29.38% (scenario 1) and 22.19% (scenario 2) for full-term infants and a decrease of 0.99% (scenario 1) and 18.88% (scenario 2) for premature infants, probably because of the higher incidence of wP-related AEs and associated costs in premature infants. With a 100% replacement rate, the budget impact for full-term infants and full-term plus premature infants was 23.73% and 21.80% (scenario 1), respectively, and 13.02% and 11.14% (scenario 2), respectively, of the national immunization program budget. The variables with most impact were the hexavalent vaccine price and costs associated with the pentavalent safety profile. CONCLUSIONS: Incorporation of the hexavalent vaccine in the Expanded Program on Immunization schedule would lead to an increase in spending largely mitigated by reduced AE incidence and reduced logistic and social costs.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacunas contra Haemophilus/economía , Vacunas contra Hepatitis B/economía , Programas de Inmunización , Vacuna Antipolio de Virus Inactivados/economía , Colombia , Humanos , Programas de Inmunización/economía , Inmunización Secundaria , Lactante , Vacunas Combinadas/economíaRESUMEN
BACKGROUND: The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio 'end-game' strategy. METHODS: We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26). RESULTS: The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme. CONCLUSIONS: The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Sustitución de Medicamentos/economía , Vacunas contra Haemophilus/administración & dosificación , Vacunas contra Haemophilus/economía , Vacunas contra Hepatitis B/administración & dosificación , Vacunas contra Hepatitis B/economía , Poliomielitis/prevención & control , Vacuna Antipolio de Virus Inactivados/administración & dosificación , Vacuna Antipolio de Virus Inactivados/economía , Vacuna Antipolio Oral/administración & dosificación , Vacuna Antipolio Oral/economía , Vacunación/economía , Chile , Costos y Análisis de Costo , Humanos , Esquemas de Inmunización , Lactante , Vacunas Combinadas/administración & dosificación , Vacunas Combinadas/economíaRESUMEN
Introduction: Across Europe, immunization programs have brought immense benefits to the prevention of infectious diseases. The vaccines used are procured through a variety of models such as tenders and Pricing & Reimbursement. However, to date, the impact of the procurement method on the performance and sustainability of vaccination programs and on public health has received little attention.Areas covered: Drawing on a review of the academic and policy literature, complemented by an interview program with stakeholders involved in the procurement of vaccines, the authors have documented the relationship between procurement method dynamics and the level of protection against vaccine-preventable diseases in Germany, Italy, Spain and Romania for, measles-containing vaccines, hexavalent and influenza vaccines.Expert opinion: Price-based tenders can contribute to vaccine supply issues, discourage the provision of value-added services supporting vaccination coverage and disincentives future R&D. Although it is observed that price-based tenders can intensify competition in the short term, there can be unintended consequences such as damage to long-term competition. As European countries are committed to strengthen their immunization programs, they should consider the implications of current vaccine procurement models on the vaccine ecosystem and on public health.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/provisión & distribución , Vacunas contra Haemophilus/provisión & distribución , Vacunas contra Hepatitis B/provisión & distribución , Vacunas contra la Influenza/provisión & distribución , Vacuna Antisarampión/provisión & distribución , Vacuna Antipolio de Virus Inactivados/provisión & distribución , Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Europa (Continente) , Vacunas contra Haemophilus/economía , Vacunas contra Hepatitis B/economía , Humanos , Programas de Inmunización/economía , Programas de Inmunización/organización & administración , Vacunas contra la Influenza/economía , Vacuna Antisarampión/economía , Vacuna Antipolio de Virus Inactivados/economía , Salud Pública , Cobertura de Vacunación , Vacunas Combinadas/economía , Vacunas Combinadas/provisión & distribuciónRESUMEN
BACKGROUND: To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV). METHODS: Based on variability in disease burden, strength of health system and economic status, we selected four states in India: Bihar, New Delhi, Maharashtra and Tamil Nadu. We used secondary data sources to estimate the number of under-5 deaths averted from Hib, pneumococcus and rotavirus in each state and back-calculated the total cases averted. We synthesized available data to estimate the disease burden, treatment cost, caretaker productivity loss and vaccine coverage in each state. A Delphi Survey and roundtable among Indian experts was conducted to reach consensus on model inputs. RESULTS: By scaling up coverage of Hib, PCV and RVV, India could save over US$1 billion (uncertainty range: US$0.9-US$2.4 billion) in economic benefits and avert more than 90,000 needless child deaths each year. An estimated US$1 billion (US$0.9-US$2 billion) or 88% of the total amount of cost savings would be attributable to lost productivity due to premature pneumococcal death. Another US$112.8 million (US$105-297 million), or 10% of the total cost would be accounted by costs related to loss of productivity due to disability as a result of these diseases. Treatment costs of Hib, pneumococcal disease and rotavirus gastroenteritis, would account for US$8.4 million (US$4-12 million) or <1% of the total costs of these diseases. Finally, caretaker productivity loss from seeking care would represent US$1.5 million (US$ 1-4.9 million). Cost savings varied by vaccine, coverage scenarios and states. CONCLUSIONS: Hib, PCV and RVV vaccine introduction in India can result in immediate benefits to the government and households in terms of savings.
Asunto(s)
Análisis Costo-Beneficio , Vacunas contra Haemophilus/economía , Programas de Inmunización , Vacunas Neumococicas/economía , Vacunas contra Rotavirus/economía , Cápsulas Bacterianas , Preescolar , Costo de Enfermedad , Infecciones por Haemophilus/economía , Infecciones por Haemophilus/prevención & control , Costos de la Atención en Salud , Humanos , India , Lactante , Recién Nacido , Infecciones Neumocócicas/economía , Infecciones Neumocócicas/prevención & control , Infecciones por Rotavirus/economía , Infecciones por Rotavirus/prevención & control , Vacunación , Vacunas Conjugadas/economíaRESUMEN
OBJECTIVE: The aims of this study were to estimate the cost-effectiveness of the Haemophilus influenzae type b (Hib) vaccine for the prevention of childhood pneumonia, meningitis and other vaccine-preventable diseases in mainland China from a societal perspective and to provide information about the addition of the Hib vaccine to Chinese immunization programs. METHODS: A decision tree and the Markov model were used to estimate the costs and effectiveness of the Hib vaccine versus no Hib vaccine for a birth cohort of 100,000 children in 2016. The disease burden was estimated from the literature, statistical yearbooks and field surveys. Vaccine costs were calculated from government reports and the United Nations International Children's Emergency Fund (UNICEF) website. The WHO cost-effectiveness thresholds were used to evaluate the Hib vaccine intervention. A one-way sensitivity analysis and probabilistic sensitivity analysis were performed to evaluate the parameter uncertainties. RESULTS: Within the hypothetical cohort, under a vaccination coverage of 90%, the Hib vaccine could reduce 91.4% of Hib pneumonia and 88.3% of Hib meningitis; the Hib vaccine could also prevent 25 deaths, 24 meningitis sequelae cases and 9 hearing loss cases caused by Hib infection. From a societal perspective, the incremental cost-effectiveness ratio (ICER) of the Hib vaccine compared with no vaccination was US$ 13,640.1 at the market price, which was less than 3 times the GDP per capita of China in 2016. The ICER of the Hib vaccine was US$ -59,122.9 at the UNICEF price, indicating a cost savings. The largest portion of the uncertainty in the result was caused by the annual incidence of all-cause pneumonia, proportion of pneumonia caused by Hi, vaccine costs per dose, annual incidence of Hib meningitis and costs per episode of meningitis. The models were robust considering parameter uncertainties. CONCLUSION: The Hib vaccine is a cost-effective intervention among children in mainland China. The cost of Hib vaccine should be reduced, and it should be introduced into Chinese immunization programs.
Asunto(s)
Costo de Enfermedad , Análisis Costo-Beneficio , Vacunas contra Haemophilus/economía , Meningitis por Haemophilus/epidemiología , Neumonía/epidemiología , Cápsulas Bacterianas , China/epidemiología , Estudios de Cohortes , Ahorro de Costo , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/inmunología , Haemophilus influenzae tipo b/patogenicidad , Costos de la Atención en Salud , Humanos , Incidencia , Lactante , Recién Nacido , Cadenas de Markov , Vacunación Masiva/economía , Meningitis por Haemophilus/economía , Meningitis por Haemophilus/microbiología , Meningitis por Haemophilus/prevención & control , Modelos Estadísticos , Neumonía/economía , Neumonía/microbiología , Neumonía/prevención & controlRESUMEN
AIMS: The World Health Organization (WHO) recommends the use of Haemophilus influenzae type b (Hib) conjugate vaccines, but China and Thailand have not used Hib vaccination in their national immunization programs. This systematic review aimed to update published economic evaluations of Hib vaccinations and to determine factors that potentially affected their cost-effectiveness. METHODS: Searches were performed from the inception until December 2015 using 13 databases: CAB direct; CEA registry; EconLit; EMBASE; E-library; NHSEED; PAHO; POPLINE; PubMed; Redalyc project; RePEc; SciELO; and WHOLIS. Reference lists of relevant studies and grey literature were also searched. Full economic evaluations of Hib vaccination with results of costs and outcomes were included. The WHO checklist was used to evaluate the quality of the included studies. Data from eligible studies were extracted using a standardized data collection form. RESULTS: Out of 830 articles, 27 were included. Almost half of the studies (12/27) were conducted in high-income countries. Twelve studies (12/27) investigated the Hib vaccine as an addition to the existing vaccination program. Most studies (17/27) examined a 3-dose schedule of Hib vaccine. Nineteen studies (19/27) reported the model used, where all were decision tree models. Most of the studies (23/27) demonstrated an economic value of Hib vaccination programs, key influential parameters being incidence rates of Hib disease and vaccine price. CONCLUSIONS: Hib vaccination programs are mostly found to be cost-effective across geographic regions and country income levels, and Hib vaccination is recommended for inclusion into all national immunization programs. The findings are expected to support policy-makers for making decisions on allocating limited resources of the Hib vaccination program effectively.
Asunto(s)
Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/administración & dosificación , Vacunas contra Haemophilus/economía , Preescolar , Costo de Enfermedad , Análisis Costo-Beneficio , Países Desarrollados , Países en Desarrollo , Gastos en Salud , Humanos , LactanteRESUMEN
BACKGROUND: Health decision makers need to know the impact of the development of a new intervention on the public health and health care costs so that they can plan for economic and financial objectives. The aim of this study was to determine the budget impact of adding Haemophilus influenzae type b (Hib) as a part of a Pentavalent vaccine (Hib-HBV-DTP) to the national childhood immunization schedule of Iran. METHODS: An excel-based model was developed to determine the costs of including the Pentavalent vaccine in the national immunization program (NIP), comparing the present schedule with the previous one (including separate DTP and hepatitis B vaccines). The total annual costs included the cost of vaccination (the vaccine and syringe) and the cost of Hib treatment. The health outcome was the estimated annual cases of the diseases. The net budget impact was the difference in the total annual cost between the two schedules. Uncertainty about the vaccine effectiveness, vaccination coverage, cost of the vaccine, and cost of the diseases were handled through scenario analysis. RESULTS: The total cost of vaccination during 5 years was $18,060,463 in the previous program and $67,774,786 in the present program. Inclusion of the Pentavalent vaccine would increase the vaccination cost about $49 million, but would save approximately $6 million in the healthcare costs due to reduction of disease cases and treatment costs. The introduction of the Pentavalent vaccine resulted in a net increase in the healthcare budget expenditure across all scenarios from $43.4 million to $50.7 million. CONCLUSIONS: The results of this study showed that the inclusion of the Pentavalent vaccine in the NIP of Iran had a significant impact on the health care budget and increased the financial burden on the government. Budget impact of including Pentavalent vaccine in the national immunization schedule of Iraná .
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacunas contra Haemophilus/economía , Haemophilus influenzae tipo b/inmunología , Vacunas contra Hepatitis B/economía , Programas Nacionales de Salud/economía , Vacunas Combinadas/economía , Preescolar , Infecciones por Haemophilus/tratamiento farmacológico , Infecciones por Haemophilus/economía , Costos de la Atención en Salud , Humanos , Esquemas de Inmunización , Irán , Jeringas/economía , Vacunación/economíaRESUMEN
By September 2013, war between Sudan and South Sudan resulted in >70,000 Sudanese refugees and high pneumonia incidence among the 20,000 refugees in Yida camp, South Sudan. Using Médecins Sans Frontières (MSF)-provided data and modifying our decision-tree models, we estimated if administering Haemophilus influenzae type b (Hib)-containing (pentavalent vaccine, also with diphtheria pertussis and tetanus [DPT] and hepatitis B) and pneumococcal conjugate (PCV) vaccines were cost-effective against hospitalized pneumonia. Among children <2years old, compared with no vaccination, one- and two-doses of combined Hib-containing and PCV would avert an estimated 118 and 125 pneumonia cases, and 8.5 and 9.1 deaths, respectively. The cost per Disability-Adjusted-Life-Year averted for administering combined one- and two-doses was US$125 and US$209, respectively. MSF demonstrated that it was possible to administer these vaccines during an emergency and our analysis found it was highly cost-effective, even with just one-dose of either vaccine. Despite unknown etiology, there is strong field and now economic rationale for administering Hib and PCV during at least one humanitarian emergency.
Asunto(s)
Análisis Costo-Beneficio , Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacuna contra Difteria, Tétanos y Tos Ferina/inmunología , Vacunas contra Haemophilus/economía , Vacunas contra Haemophilus/inmunología , Vacunas contra Hepatitis B/economía , Vacunas contra Hepatitis B/inmunología , Vacunas Neumococicas/economía , Vacunas Neumococicas/inmunología , Neumonía Bacteriana/economía , Neumonía Bacteriana/prevención & control , Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , Vacunas contra Haemophilus/administración & dosificación , Vacunas contra Hepatitis B/administración & dosificación , Humanos , Lactante , Recién Nacido , Vacunas Neumococicas/administración & dosificación , Refugiados , Sudán del Sur , Vacunas Conjugadas/administración & dosificación , Vacunas Conjugadas/economía , Vacunas Conjugadas/inmunologíaRESUMEN
BACKGROUND: The reimbursement of the hexavalent vaccine (Infanrix hexa™), comprising the DTPa-IPV-Hib components and the hepatitis B recombinant in a single vaccine, was approved in France in March of 2008. The impact of its reimbursement on physicians' decisions to vaccinate infants against hepatitis B was assessed in a study conducted with general practitioners and pediatricians. METHODS: The PRALINE study (NCT01777074) was a national, cross-sectional, repeated study with two measurement periods (T1 and T2) that measured the changes in physicians' acceptance of hepatitis B vaccination of infants before and for the 3 years after the approval of the hexavalent vaccine reimbursement. Two patient registers were created for each measurement period to enroll the first 15 12- to 15-month-old infants and the first 15 24- to 27-month-old children seen by the practitioners. The proportion of eligible children receiving a hepatitis B vaccine for each physician's practice was calculated. Practitioners also answered a vaccination practice questionnaire via telephone interviews. RESULTS: Across the two study periods, 418 general practitioners and 463 pediatricians were recruited and responded to the telephone interview on their vaccination practices. The overall number of children included in the study in both study periods reached almost 20,000. In the general practitioners group, there was a significant increase in the proportion of physicians "practicing hepatitis B vaccination" (i.e., at least 50% of eligible children receiving the initial hepatitis B vaccination) in children 24-27 months old (79% T2 versus 47% T1, P-value [P]<0.001). Similarly, the proportion of pediatricians initiating hepatitis B vaccination increased from 51% (T1) to 94% (T2) (P<0.0001). General practitioners offered hepatitis B vaccination to infants more systematically in the second study period (87% T2 versus 73% T1, P<0.001) and also suggested the use of the hexavalent vaccine to more patients after reimbursement (92% T2 versus 78% T1, P<0.0001). The proportion of pediatricians offering vaccination to every infant was high at T1 (94%) and remained steady (97%) with a high use of the hexavalent vaccine (94% T1 and 96% T2). CONCLUSION: The PRALINE study shows a significant and immediate change in the hepatitis B vaccination practices of general practitioners and pediatricians following hexavalent vaccine reimbursement with a significant increase in hepatitis B vaccine coverage in infants.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacunas contra Haemophilus/economía , Vacunas contra Hepatitis B/economía , Hepatitis B/prevención & control , Reembolso de Seguro de Salud/estadística & datos numéricos , Aceptación de la Atención de Salud , Vacuna Antipolio de Virus Inactivados/economía , Salud Pública/economía , Preescolar , Estudios Transversales , Vacuna contra Difteria, Tétanos y Tos Ferina/uso terapéutico , Femenino , Francia/epidemiología , Medicina General/economía , Medicina General/estadística & datos numéricos , Vacunas contra Haemophilus/uso terapéutico , Vacunas contra Hepatitis B/uso terapéutico , Humanos , Lactante , Masculino , Aceptación de la Atención de Salud/estadística & datos numéricos , Pediatría/economía , Pediatría/estadística & datos numéricos , Vacuna Antipolio de Virus Inactivados/uso terapéutico , Vacunación/economía , Vacunación/estadística & datos numéricos , Vacunas Combinadas/economía , Vacunas Combinadas/uso terapéuticoRESUMEN
The introduction of pentavalent vaccine containing Haemophilus influenzae type b antigen in Indonesia's National Immunization Program occurred nearly three decades after the vaccine was first available in the United States and 16 years after Indonesia added hepatitis B vaccine into the program. In this study, we analyzed the process that led to the decision to introduce pentavalent vaccine in Indonesia. Using process tracing and case comparison, we used qualitative data gathered through interviews with key informants and data extracted from written sources to identify four distinct but interrelated processes that were involved in the decision making: (a) pentavalent vaccine use policy process, (b) financing process, (c) domestic vaccine development process and (d) political process. We hypothesized that each process is associated with four necessary conditions that are jointly sufficient for the successful introduction of pentavalent vaccine in Indonesia, namely (a) an evidence-based vaccine use recommendation, (b) sufficient domestic financing capacity, (c) sufficient domestic vaccine manufacturing capacity and (d) political support for introduction. This analysis of four processes that led to the decision to introduce a new vaccine in Indonesia may help policy makers and other stakeholders understand and manage activities that can accelerate vaccine introduction in the future.
Asunto(s)
Cápsulas Bacterianas/inmunología , Vacunas contra Haemophilus/inmunología , Política de Salud , Programas de Inmunización/economía , Formulación de Políticas , Análisis Costo-Beneficio/economía , Práctica Clínica Basada en la Evidencia , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/economía , Humanos , Indonesia , Entrevistas como Asunto , Programas Nacionales de Salud/economía , Investigación CualitativaRESUMEN
BACKGROUND: Reimbursement of the hexavalent vaccine (Infanrix hexa) comprising the DTPa-IPV-Hib components and the hepatitis B valence in a single vaccine was decided in March 2008 in France. The impact of its reimbursement on the hepatitis B vaccine coverage rate was assessed in a study conducted in the general population prior to and after implementation of the reimbursement policy. METHODS: The PopCorn study (NCT01782794) was a national, cross-sectional and repeated study, with four assessment periods over 3 years, from 2009 to 2012, to assess the hepatitis B vaccine coverage in 12- to 15- and 24- to 27-month-old children, vaccinated between 2007 and 2011 and selected by the quota sampling method. Face-to-face interviews were conducted at their homes and vaccination status was collected using their child's health record. Parents were also interviewed on their perceptions and acceptance of hepatitis B vaccination. Three indicators were calculated to assess hepatitis B vaccination coverage: proportions of infants with at least one dose before 6 months of age, with at least two doses before 6 months of age and with a complete schedule at 24 months of age. RESULTS: A total of 4903 children were enrolled in the study. An overall significant increase (P-value [P<0.05]) of the three indicators of interest over the four periods of time was observed for both age groups. The proportion of children receiving hepatitis B vaccination before 6 months increased from 21% at baseline (before vaccine reimbursement) to almost 75% at the last assessment period in 2012. More than 60% of 24- to 27-month-old children received a complete schedule in 2012 compared to 33% at baseline. No significant increases in the proportions of parents "favourable" and "moderately in favour" of hepatitis B vaccination were observed across the four evaluation periods (respectively, 17-22% and 48-50%, P=0.09). CONCLUSION: The rapid increase of hepatitis B vaccination coverage suggests a significant change in hepatitis B vaccination practice related to the hexavalent vaccine's reimbursement. This change was observed in a context of stability regarding parents' perceptions and acceptance of hepatitis B vaccination and of coverage rates for other infant vaccinations.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacuna contra Difteria, Tétanos y Tos Ferina/uso terapéutico , Vacunas contra Haemophilus/economía , Vacunas contra Haemophilus/uso terapéutico , Vacunas contra Hepatitis B/economía , Vacunas contra Hepatitis B/uso terapéutico , Hepatitis B/prevención & control , Reembolso de Seguro de Salud , Vacuna Antipolio de Virus Inactivados/economía , Vacuna Antipolio de Virus Inactivados/uso terapéutico , Salud Pública/economía , Vacunación/economía , Preescolar , Miedo/psicología , Francia , Costos de la Atención en Salud , Conocimientos, Actitudes y Práctica en Salud , Hepatitis B/economía , Hepatitis B/psicología , Humanos , Lactante , Reembolso de Seguro de Salud/economía , Reembolso de Seguro de Salud/estadística & datos numéricos , Padres/psicología , Vacunación/psicología , Vacunación/estadística & datos numéricos , Vacunas Combinadas/economía , Vacunas Combinadas/uso terapéuticoRESUMEN
BACKGROUND: Antigens contained in vaccines are inherently unstable biologically; such a characteristic is conferred by their three-dimensional structure. Preserving the ability of the vaccines to protect against disease is necessary to ensure the supervision and monitoring of all steps of the cold chain. DTPa-HBV-IPV/Hib vaccine (Infanrix hexaTM, GSK Vaccines, Belgium) is designed to prevent disease due to diphtheria, tetanus, pertussis (DTP), hepatitis B virus (HBV), poliomyelitis and Haemophilus influenzae type b (Hib); it was first licensed for use in Europe in 2000 and is currently licensed in at least 95 countries. Since October 2013, more than 102 million doses of GSK's DTPa-HBV-IPV/Hib vaccine have been distributed globally, with nearly 15 million doses distributed in Italy. DTPa-HBV-IPV/Hib components are stable up to a temperature of 25°C for 72 hours. Lacking of officially approved stability data may generate some concern in case of cold chain accidents. METHODS: An analysis based on collected data was carried out to estimate potential costs attributable to events of "out-of-temperature" in the stockpiling of hexavalent vaccines occurring in Italy in 2014. RESULTS: The analysis, based on real data, documented that the loss for the National Health Service (NHS) was in the range of 100,000 - 400,000 euros in one year. However, the amount of money that in principle could have been lost would have ranged between nearly half and one million euros/year. CONCLUSIONS: A substantial loss of money was avoided thanks to the availability of officially approved stability data for GSK's DTPa-HBV-IPV/Hib vaccine.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/provisión & distribución , Vacunas contra Haemophilus/provisión & distribución , Vacunas contra Hepatitis B/provisión & distribución , Vacuna Antipolio de Virus Inactivados/provisión & distribución , Antígenos/inmunología , Costos y Análisis de Costo , Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacuna contra Difteria, Tétanos y Tos Ferina/inmunología , Estabilidad de Medicamentos , Almacenaje de Medicamentos/economía , Almacenaje de Medicamentos/normas , Vacunas contra Haemophilus/economía , Vacunas contra Haemophilus/inmunología , Vacunas contra Hepatitis B/economía , Vacunas contra Hepatitis B/inmunología , Humanos , Italia , Vacuna Antipolio de Virus Inactivados/economía , Vacuna Antipolio de Virus Inactivados/inmunología , Refrigeración , Vacunas Combinadas/economía , Vacunas Combinadas/inmunología , Vacunas Combinadas/provisión & distribuciónRESUMEN
Prior to the 1980s, most vaccines were licensed based upon safety and effectiveness studies in several hundred individuals. Beginning with the evaluation of Haemophilus influenzae type b conjugate vaccines, much larger pre-licensure trials became common. The pre-licensure trial for Haemophilus influenzae oligosaccharide conjugate vaccine had more than 60,000 children and that of the seven-valent pneumococcal conjugate vaccine included almost 38,000 children. Although trial sizes for both of these studies were driven by the sample size required to demonstrate efficacy, the sample size requirements for safety evaluations of other vaccines have subsequently increased. With the demonstration of an increased risk of intussusception following the Rotashield brand rotavirus vaccine, this trend has continued. However, routinely requiring safety studies of 20,000-50,000 or more participants has two major downsides. First, the cost of performing large safety trials routinely prior to licensure of a vaccine is very large, with some estimates as high at US$200 million euros for one vaccine. This high financial cost engenders an opportunity cost whereby the number of vaccines that a company is willing or able to develop to meet public health needs becomes limited by this financial barrier. The second downside is that in the pre-licensure setting, such studies are very time consuming and delay the availability of a beneficial vaccine substantially. One might argue that in some situations, this financial commitment is warranted such as for evaluations of the risk of intussusception following newer rotavirus vaccines. However, it must be noted that while an increased risk of intussusception was not identified in large pre-licensure studies, in post marketing evaluations an increased risk of this outcome has been identified. Thus, even the extensive pre-licensure evaluations conducted did not identify an associated risk. The limitations of large Phase III trials have also been demonstrated in efficacy trials. Notably, pre-licensure trials of pneumococcal conjugate severely underestimated their true effect and cost-effectiveness. In fact, in discussions prior to vaccine introduction in the USA for PCV7, the vaccine was said to be not cost-effective and some counseled against its introduction. In reality, following introduction, PCV7 has been shown to be highly cost-effective. In the last decade, new methods have been identified using large linked databases such as the Vaccine Safety Datalink in the USA that allow identification of an increased risk of an event within a few months of vaccine introduction and that can screen for unanticipated very rare events as well. In addition, the availability of electronic medical records and hospital discharge data in many settings allows for accurate assessment of vaccine effectiveness. Given the high financial and opportunity cost of requiring large pre-licensure safety studies, consideration could be given to 'conditional licensure' of vaccines whose delivery system is well characterized in a setting where sophisticated pharmacovigilance systems exist on the condition that such licensure would incorporate a requirement for rapid cycle and other real-time evaluations of safety and effectiveness following introduction. This would actually allow for a more complete and timely evaluation of vaccines, lower the financial barrier to development of new vaccines and thus allow a broader portfolio of vaccines to be developed and successfully introduced.
Asunto(s)
Ensayos Clínicos Fase III como Asunto/economía , Análisis Costo-Beneficio/economía , Vacunas contra Haemophilus/economía , Vacuna Neumocócica Conjugada Heptavalente/economía , Vacunas contra Rotavirus/economía , Vacunación/economía , Cápsulas Bacterianas/inmunología , Niño , Preescolar , Aprobación de Drogas/economía , Infecciones por Haemophilus/inmunología , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/inmunología , Haemophilus influenzae tipo b/inmunología , Vacuna Neumocócica Conjugada Heptavalente/inmunología , Humanos , Meningitis Meningocócica/inmunología , Meningitis Meningocócica/prevención & control , Neisseria meningitidis/inmunología , Rotavirus/inmunología , Infecciones por Rotavirus/inmunología , Infecciones por Rotavirus/prevención & control , Vacunas contra Rotavirus/inmunología , Vacunas Atenuadas/economía , Vacunas Atenuadas/inmunología , Vacunas Conjugadas/efectos adversos , Vacunas Conjugadas/economía , Vacunas Conjugadas/inmunologíaRESUMEN
BACKGROUND: With GAVI support, Vietnam introduced Haemophilus influenzae type b (Hib) vaccine in 2010 without evidence on cost-effectiveness. We aimed to analyze the cost-effectiveness of Hib vaccine from societal and governmental perspectives. METHOD: We constructed a decision-tree cohort model to estimate the costs and effectiveness of Hib vaccine versus no Hib vaccine for the 2011 birth cohort. The disease burden was estimated from local epidemiologic data and literature. Vaccine delivery costs were calculated from governmental reports and 2013 vaccine prices. A prospective cost-of-illness study was conducted to estimate treatment costs. The human capital approach was employed to estimate productivity loss. The incremental costs of Hib vaccine were divided by cases, deaths, and disability-adjusted life years (DALY) averted. We used the WHO recommended cost-effectiveness thresholds of an intervention being highly cost-effective if incremental costs per DALY were below GDP per capita. RESULT: From the societal perspective, incremental costs per discounted case, death and DALY averted were US$ 6252, US$ 26,476 and US$ 1231, respectively; the break-even vaccine price was US$ 0.69/dose. From the governmental perspective, the results were US$ 6954, US$ 29,449, and US$ 1373, respectively; the break-even vaccine price was US$ 0.48/dose. Vietnam's GDP per capita was US$ 1911 in 2013. In deterministic sensitivity analysis, morbidity and mortality parameters were among the most influential factors. In probabilistic sensitivity analysis, Hib vaccine had an 84% and 78% probability to be highly cost-effective from the societal and governmental perspectives, respectively. CONCLUSION: Hib vaccine was highly cost-effective from both societal and governmental perspectives. However, with GAVI support ending in 2016, the government will face a six-fold increase in its vaccine budget at the 2013 vaccine price. The variability of vaccine market prices adds an element of uncertainty. Increased government commitment and improved resource allocation decision making will be necessary to retain Hib vaccine.
Asunto(s)
Transmisión de Enfermedad Infecciosa/prevención & control , Infecciones por Haemophilus/economía , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/economía , Vacunas contra Haemophilus/inmunología , Haemophilus influenzae tipo b/inmunología , Preescolar , Costo de Enfermedad , Análisis Costo-Beneficio , Femenino , Infecciones por Haemophilus/epidemiología , Infecciones por Haemophilus/microbiología , Vacunas contra Haemophilus/administración & dosificación , Costos de la Atención en Salud , Humanos , Lactante , Recién Nacido , Masculino , Estudios Prospectivos , Vietnam/epidemiologíaRESUMEN
BACKGROUND: Pneumonia is a leading cause of death among children less than five years old during humanitarian emergencies. Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae are the leading causes of bacterial pneumonia. Vaccines for both of these pathogens are available to prevent pneumonia. Problem This study describes an economic analysis from a publicly funded health care system perspective performed on a birth cohort in Somalia, a country that has experienced a protracted humanitarian emergency. METHODS: An impact and cost-effectiveness analysis was performed comparing: no vaccine, Hib vaccine only, pneumococcal conjugate vaccine 10 (PCV10) only, and both together administered through supplemental immunization activities (SIAs). The main summary measure was the incremental cost per disability-adjusted life-years (DALYs) averted. One-way sensitivity analysis was conducted for uncertainty in parameter values. RESULTS: Each SIA would avert a substantial number of cases and deaths. Compared with no vaccine, the DALYs averted by two SIAs for two doses of Hib vaccine was US $202.93 (lower and upper limits: $121.80-$623.52), two doses of PCV10 was US $161.51 ($107.24-$227.21), and two doses of both vaccines was US $152.42 ($101.20-$214.42). Variables that influenced the cost-effectiveness for each strategy most substantially were vaccine effectiveness, case fatality rates (CFRs), and disease burden. CONCLUSIONS: The World Health Organization (WHO) defines a cost-effective intervention as costing one to three times the per capita gross domestic product (GDP; in 2011, for Somalia=US $112). Based on the presented model, Hib vaccine alone, PCV10 alone, or Hib vaccine and PCV10 given together in SIAs are cost-effective interventions in Somalia. The WHO/Strategic Advisory Group of Experts decision-making factors for vaccine deployment appear to have all been met: the disease burden is large, the vaccine-related risk is low, prevention in this setting is more feasible than treatment, the vaccine duration probably is sufficient for the vulnerable period of the child's life, cost is reasonable, and herd immunity is possible.
Asunto(s)
Vacunas contra Haemophilus/economía , Vacunas Neumococicas/economía , Neumonía Bacteriana/prevención & control , Altruismo , Análisis Costo-Beneficio , Técnicas de Apoyo para la Decisión , Urgencias Médicas , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae , Humanos , Programas de Inmunización/economía , Vacunas Neumococicas/uso terapéutico , Neumonía Neumocócica/prevención & control , Somalia , Vacunas ConjugadasRESUMEN
The incidence of Haemophilus Influenzae type b (Hib) disease in developed countries has decreased since the introduction of Hib conjugate vaccines in their National Immunization Programs (NIP). In countries where Hib vaccination is not applied routinely, due to limited availability and high cost of the vaccines, invasive Hib disease is still a cause of mortality. Through the development of a production process for a Hib conjugate vaccine and related quality control tests and the transfer of this technology to emerging vaccine manufacturers in developing countries, a substantial contribution was made to the availability and affordability of Hib conjugate vaccines in these countries. Technology transfer is considered to be one of the fastest ways to get access to the technology needed for the production of vaccines. The first Hib conjugate vaccine based on the transferred technology was licensed in 2007, since then more Hib vaccines based on this technology were licensed. This paper describes the successful development and transfer of Hib conjugate vaccine technology to vaccine manufacturers in India, China and Indonesia. By describing the lessons learned in this process, it is hoped that other technology transfer projects can benefit from the knowledge and experience gained.
Asunto(s)
Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/economía , Transferencia de Tecnología , Cápsulas Bacterianas , China , Países en Desarrollo , Haemophilus influenzae tipo b , Humanos , India , Indonesia , Meningitis por Haemophilus/prevención & control , Tecnología Farmacéutica , Vacunas Conjugadas/economíaRESUMEN
BACKGROUND: Haemophilus influenzae type b (Hib) vaccine and pneumococcal conjugate vaccine (PCV) are relatively expensive, newly introduced vaccines in China. This study evaluates the impact of residency and urbanicity on Hib vaccine and PCV coverage for children aged 2 to 7 years living in Shanghai, China, in August 2012. METHODS: In this exploratory cohort study, a sample of children aged 2 to 7 years, all of whom were eligible to have received the complete series of Hib vaccine and PCV, was obtained from the Shanghai Immunization Program Information System. Three measures of vaccination coverage for Hib vaccine and PCV were examined: dose 1 coverage, series completion, and timeliness of dose 1 vaccination. Multivariable binomial regression was used to estimate the difference in vaccination coverage between locals and the floating population. RESULTS: Dose 1 coverage was 50.9% for Hib vaccine and 11.4% for PCV for the 28,141 abstracted pediatric records. For both vaccines, dose 1 coverage was higher in locals than in the floating population. The disparity in coverage between locals and the floating population was greater in suburban areas than urban areas. Of all children who received dose 1, 79.7% completed the Hib vaccine series, and 91.3% completed the PCV series. Timely dose 1 coverage was 8.2% for Hib vaccine and 0.5% for PCV. CONCLUSION: Low vaccination coverage and extremely low levels of timely dose 1 vaccination indicate that current vaccination efforts are inadequate to reduce the burden of Hib and pneumococcal disease among Chinese children, especially infants. Government funding of the Hib vaccine and PCV through the Expanded Program on Immunization would increase uptake and could also ensure that improvement in the timeliness of administration and series completion is targeted for all demographic groups.
Asunto(s)
Cápsulas Bacterianas/inmunología , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/inmunología , Haemophilus influenzae tipo b/inmunología , Programas de Inmunización/organización & administración , Vacunación , Niño , Preescolar , China , Femenino , Infecciones por Haemophilus/inmunología , Infecciones por Haemophilus/microbiología , Vacunas contra Haemophilus/administración & dosificación , Vacunas contra Haemophilus/economía , Humanos , Esquemas de Inmunización , Masculino , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Población Urbana , Vacunas ConjugadasRESUMEN
We explored market factors that affect pediatric combination vaccine uptake in the US public-sector pediatric vaccine market. We specifically examined how Pediarix and Pentacel earned a place in the 2009-2012 lowest overall cost formulary. Direct competition between Pediarix and Pentacel is driven by the indirect presence of the Merck Haemophilus influenzae type b vaccine and the Recommended Childhood Immunization Schedule requirement for a hepatitis B birth dose. The resulting analysis suggests that Pentacel would never have earned a place in the lowest overall cost formulary for 2009-2012 federal contract prices for any cost of an injection unless the Merck H influenzae type b advantage was ignored and the hepatitis B birth dose administration cost was recognized by health care providers in designing the lowest overall cost formularies.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/economía , Vacunas contra Haemophilus/economía , Vacunas contra Hepatitis B/economía , Vacuna Antipolio de Virus Inactivados/economía , Niño , Preescolar , Vacuna contra Difteria, Tétanos y Tos Ferina/uso terapéutico , Costos de los Medicamentos , Industria Farmacéutica/economía , Vacunas contra Haemophilus/uso terapéutico , Vacunas contra Hepatitis B/uso terapéutico , Humanos , Programas de Inmunización/economía , Lactante , Recién Nacido , Vacuna Antipolio de Virus Inactivados/uso terapéutico , Estados Unidos , Vacunas Combinadas/economía , Vacunas Combinadas/uso terapéuticoRESUMEN
The 7-valent pneumococcal conjugate vaccine (PCV7) and Haemophilus influenzae type b (Hib) vaccine reduce nasopharyngeal carriage of vaccine-type bacteria, which may in turn influence the presence of other nasopharyngeal bacterial pathogens. To investigate this possibility, nasopharyngeal carriage of potential pathogens was examined before and after official financial support was provided to offer the PCV7 and Hib vaccines in healthy children attending a day care centre in Japan during 2011-2012. Despite a virtual disappearance of PCV7 serotypes over time, the overall pneumococcal carriage rate remained unchanged. Although others have reported an increase in PCV13 serotypes following PCV7 vaccination, only non-PCV13 serotypes were observed to have increased in this study. The majority of H. influenzae isolates were non-typeable and Hib was not found. Our data identified an unexpected pattern of pneumococcal serotype replacement following PCV7. Continuous monitoring of pneumococcal carriage is important for decisions regarding the future of national vaccination policy in Japan.